Clinical Trial Update: Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients [Phase 2, Phase 3]

View source ↗

Summary

The Phase 2b/3 study of ABX464 in moderate to severe active Crohn's disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• ABX464 (ABX464)

Snippet

Sponsor: Abivax S.A. | Conditions: Crohn Disease | Phase 2, Phase 3 | Status: WITHDRAWN